Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ONCOSCREEN

Financiado

Cerrado

A European shield against colorectal cancer based on novel, more precise and aff...

A European shield against colorectal cancer based on novel, more precise and affordable risk-based screening methods and viable policy pathways With Colorectal Cancer (CRC) being accountable for 12.4% of all deaths due to cancer, and with only 14% of EU citizens participating in screening programmes, there is an urgent need for accurate, non-invasive, cost-effective scree... ver más

31/12/2026

EXUS SOFTWARESINGL...

13M€

Presupuesto del proyecto: 13M€

Líder del proyecto

EXUS SOFTWARE MONOPROSOPI ETAIRIA PERIORISMEN... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 38 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-11-28

HORIZON-MISS-2021-CANCER-02-01: Develop new methods and technologie... ExpectedOutcome:Prevention is the most cost-effective long-term cancer control strategy. In EU-27 an...

I+D

Cerrada hace 2 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

38 Participantes

EXUS SOFTWARESINGLE MEMBER L...

1.02M€ | Lider

EUROPACOLON PORTUGAL ASSOCIA...

115.00K€ | Participante

ASSOCIATION GERCOR

352.50K€ | Participante

RESEARCH UNIVERSITY INSTITUT...

625.75K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

ONCOSCREEN A European “shield” against colorectal cancer based on novel... 13M€ Cerrado

ColoFast Developing a Non Invasive Kit for Early Colorectal Cancer De... 3M€ Cerrado

ColonScan A simple to use accurate and cost effective blood test for... 71K€ Cerrado

AMX DATA Identification of risk factors for the development of colore... 130K€ Cerrado

MyPeBS International Randomized Study Comparing personalized Risk... 12M€ Cerrado

PTQ2020-010990 VALIDACIÓN CLÍNICA Y ANALÍTICA DE UN TEST DE DETECCIÓN TEMPR... 38K€ Cerrado

Duración del proyecto: 49 meses Fecha Inicio: 2022-11-28
Fecha Fin: 2026-12-31

Líder del proyecto

EXUS SOFTWARE MONOPROSOPI ETAIRIA PERIORISMEN... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 13M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto With Colorectal Cancer (CRC) being accountable for 12.4% of all deaths due to cancer, and with only 14% of EU citizens participating in screening programmes, there is an urgent need for accurate, non-invasive, cost-effective screening tests based on novel technologies and an increased awareness on the disease and its detection. Furthermore, personalized approaches for screening are needed, to consider genetic and other socioeconomic variables and environmental stressors that lead to different onsets of the disease. ONCOSCREEN responds to these challenges by developing a risk-based, population-level stratification methodology for CRC, to account for genetic prevalence, socio-economic status, and other factors. It complements this methodology by a) developing a set of novel, practical, and low-cost screening technologies with high sensitivity and specificity, b) leveraging AI to improve existing methodologies for CRC screening, allowing for the early detection of polyps and provision of a personalized risk status stratification, and c) providing a mobile app for self-monitoring and CRC awareness raising. Furthermore, ONCOSCREEN develops an Intelligent Analytics dashboard for policy makers facilitating effective policy making at regional and national levels. Through a multi-level campaign, the above-mentioned solutions are tested and validated. For the clinical solutions specifically, a clinical validation study has been planned with the participation of 4100 enrolled patients/citizens. To ensure the adoption of the developed solutions by the healthcare systems, their cost-effectiveness and financial viability will be assessed. The 48-months duration project will be implemented by a multidisciplinary consortium comprising of 38 partners, including technical solutions providers, hospitals, Ministries of Health as policy makers, legal and ethics experts, Insurance companies, involving actively end-users/citizens in all phases of implementation through targeted workshops. This action is part of the Cancer Mission cluster of projects on ‘Prevention, including Screening.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores